Damgov, I, Bartosova, M, Marinovic, I, Istanbuly, O, Kieser, M, Lambie, MR, Davies, SJ, Schmitt, CP, Vychytil, A, Raby, A-C, Colmont, C, Aufricht, C, Johnson, DW, Fraser, D, Eringa, E, Morelle, J, Valdivielso, JM, Kratochwill, K, Jakulj, L, Vervloet, M, Ruiz-Ortega, M, Devuyst, O, Rossignol, P, Rutherford, P, Herzog, R and Meran, S (2023) IMPROVE-PD Finder: A Web-Based Platform to Search and Share Peritoneal Dialysis Biobank, Registry, and Clinical Trial Metadata. Kidney International Reports. ISSN 2468-0249

[thumbnail of 1-s2.0-S2468024923000049-main.pdf]
1-s2.0-S2468024923000049-main.pdf - Accepted Version

Download (585kB) | Preview


Peritoneal dialysis (PD) is a life-sustaining kidney replacement therapy for the increasing number of people with permanent kidney failure across all age groups worldwide. Although PD potentially offers socioeconomic and performance benefits over hemodialysis, both treatments severely accelerate complications of chronic kidney disease, in particular atherosclerotic disease progression that worsens outcomes when compared with non-dialysis patients.1 Improved understanding of the underlying molecular pathogenic mechanisms should help in the design of interventions that improve outcomes.2 Current state of the art in PD research, however, faces major limitations. Although there are numerous in vitro and ex vivo studies on complex cellular and molecular networks active in PD3, 4, 5 and in vivo animal models of PD6, 7, 8 that provide in-depth pathomechanistic insights and allow identification of promising therapeutic targets,9,S1,S2 translation into clinical studies is a major challenge.S3 Patient studies that aim to substantiate experimental findings with definitive clinical outcome data are mostly small. As a result, they have not provided sufficient power to derive meaningful or clinically implementable conclusions.2 Basic PD technique has hardly changed over decades, despite high PD-related complication rates. Randomized prospective trials with hard clinical end points studied with adequate power are difficult to realize in a multifactorial setting with low patient numbers (360,000 worldwide) and are associated with high costs. To overcome these barriers intermediate end points such as PD effluent biomarkers associated (but not necessarily causally related) with hard clinical end points and composite end points are often studied.S4,S5 Equally, combining analyses of existing cohort studies and trial data through collaborative sharing might be of considerable benefit.

Item Type: Article
Additional Information: ª 2023 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Subjects: R Medicine > R Medicine (General)
R Medicine > RC Internal medicine > RC902 Nephrology
Divisions: Faculty of Medicine and Health Sciences > School of Medicine
Related URLs:
Depositing User: Symplectic
Date Deposited: 14 Feb 2023 08:37
Last Modified: 14 Feb 2023 08:37
URI: https://eprints.keele.ac.uk/id/eprint/11925

Actions (login required)

View Item
View Item